Fig. 1From: Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patientsa Number of relapses in the 24 months preceding V1 (left) and between V1 and V2 in naïve (green) and switchers (red) (right). b Expanded disability status score (EDSS) at V1 (left); EDSS change between V1 and V2 in naïve (green) and switchers (red) (right)Back to article page